It is intended to provide a highly safe, orally administrable preventive and/or therapeutic agent for thromboembolism that is intended for a thromboembolism patient with severe renal impairment. The present invention provides a preventive and/or therapeutic agent for thromboembolism, containing edoxaban, wherein the preventive and/or therapeutic agent is used so that the edoxaban is administered at a dose of 15 mg once a day to an atrial fibrillation patient with severe renal impairment.